Since 1994, Dr. Tong Xiaowen has been engaged in the research of tumor gene therapy in the United States and Germany, published more than 70 academic papers internationally, won two American patents, and served as the special rapporteur and chairman of international seminars for many times. He was one of the two foreign writers specially invited by the American Gynecology and Obstetrics Series in 2000. Dr. Tong Xiaowen has received good clinical training in gynecology and holds medical licenses from China, the United States and Germany. He has worked in China, the United States and Germany for 0/5 years and accumulated rich clinical experience. In recent years, nearly 2000 related operations have been successfully completed, which has been well received by colleagues in the United States and Germany.

Five years of training in the United States and eight years of training in Germany, he was once one of the best people in minimally invasive gynecological surgery in Germany.

Tong Xiaowen, who has a doctor's license from China, Germany and the United States, is the head of the gene therapy group of ovarian cancer in the Obstetrics and Gynecology Hospital of the University of Freiburg, Germany, and has won the SGI Award from the President of the United States.

He is currently a member of the pelvic floor group of obstetrics and gynecology of Chinese Medical Association, a member of Chinese Medical Association, the chairman of the Rehabilitation Medicine Society of Shanghai Medical Association, the standing member of the Obstetrics and Gynecology Society, and the head of the pelvic floor group.